Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28323312 | 0.92 | MAPK1 (0.55) | MAPK1POLBNAMPTALDH1A1USP2 | |
| SCHEMBL11833579 | 0.86 | MAPK1 (0.59) | MAPK1POLBALDH1A1USP2TSHR | |
| SCHEMBL16357643 | 0.85 | MAPK1 (0.57) | MAPK1POLBALDH1A1USP2TSHR | |
| Hydrochloric Acid SCHEMBL6913635 | 0.85 | MAPK1 (0.57) | MAPK1POLBALDH1A1USP2TSHR | |
| Hydrochloric Acid SCHEMBL7632441 | 0.85 | MAPK1 (0.57) | MAPK1POLBALDH1A1USP2TSHR | |
| SCHEMBL14586642 | 0.84 | POLB (0.59) | POLBNAMPTALDH1A1TSHRMEN1 | |
| SCHEMBL12155872 | 0.84 | MAPT (0.59) | POLBNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL14037733 | 0.83 | NAMPT (0.64) | MAPK1POLBNAMPTALDH1A1USP2 | |
| SCHEMBL16435180 | 0.83 | NAMPT (0.64) | MAPK1POLBNAMPTALDH1A1USP2 | |
| SCHEMBL23544884 | 0.83 | PANK3 (0.57) | MAPK1POLBNAMPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114051-B | Antimicrobial compositions | 联合利华知识产权控股有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3500234-B1 | AN ANTIMICROBIAL COMPOSITION | UNILEVER NV (NL) | 2020-12-16 | — | — | EP | claimed |
| US-10617621-B2 | Antimicrobial composition | CONOPCO, INC. (US) | 2020-04-14 | — | — | US | claimed |
| CN-110114051-A | Antimicrobial compositions | 荷兰联合利华有限公司 | 2019-08-09 | — | — | CN | claimed |
| US-20190201312-A1 | ANTIMICROBIAL COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2019-07-04 | — | — | US | claimed |
| EP-3500234-A1 | AN ANTIMICROBIAL COMPOSITION | Unilever N.V. (NL) | 2019-06-26 | — | — | EP | claimed |
| WO-2018033466-A1 | AN ANTIMICROBIAL COMPOSITION | UNILEVER N.V. (NL) | 2018-02-22 | — | — | WO | claimed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-7521544-B2 | Method and apparatus for the use of [11C] carbon monoxide in labeling synthesis by photo-initiated carbonylation | GE HEALTHCARE LIMITED (GB) | 2009-04-21 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. | 2008-10-09 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070043213-A1 | Method and apparatus for the use of [11c] carbon monoxide in labeling synthesis by photo-intiated carbonylation | GE HEALTHCARE LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043213-A1 | Method and apparatus for the use of [11c] carbon monoxide in labeling synthesis by photo-intiated carbonylation | PPOX, HCCS, CPS1 | MAPK1 4399/4885POLB 608/4885NAMPT 1354/4885 |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | MAPK1 1902/4885POLB 635/4885NAMPT 1185/4885 |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | MAPK1 1/4885POLB 3197/4885NAMPT 1451/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPK1 281/4885POLB 1934/4885NAMPT 1681/4885 |
| US-20190201312-A1 | ANTIMICROBIAL COMPOSITION | LPO, POLR1C, GPX4 | MAPK1 3948/4885POLB 365/4885NAMPT 989/4885 |
| US-10617621-B2 | Antimicrobial composition | LPO, POLR1C, GPX4 | MAPK1 3948/4885POLB 365/4885NAMPT 989/4885 |
| US-20080249081-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | MRGPRX2, MRGPRX4, MRGPRX1 | MAPK1 2601/4885POLB 4342/4885NAMPT 1739/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPK1 281/4885POLB 1934/4885NAMPT 1681/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | MAPK1 477/4885POLB 3534/4885NAMPT 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.